AIDX 20/20 Biolabs, Inc.
Services-Testing Laboratories · Nasdaq · SEC CIK 1139685 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin29.7%
Operating margin-249.2%
Net margin-317.8%
FCF margin—
EBITDA margin-246.8%
Returns
ROE-1,768.6%
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets56.8%
Debt / equity0.00x
Current ratio1.62x
Interest coverage-7.51x
Cash quality & payout
Operating cash flow / net income0.52x
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $380,216 | $730,571 | $353,375 | $538,274 | $417,979 | $535,060 | $553,820 |
| Cost of revenue | $283,343 | $425,844 | $290,491 | $407,857 | $272,913 | $371,796 | $388,025 |
| Gross profit | $96,873 | $304,727 | $62,884 | $130,417 | $145,066 | $163,264 | $165,795 |
| R&D expense | $123,385 | $257,632 | $153,482 | $130,554 | $131,060 | $194,124 | $136,831 |
| SG&A expense | $1.36M | $1.29M | $1.35M | $912,709 | $814,179 | $814,811 | $801,144 |
| Operating income | -$1.39M | -$1.24M | -$1.44M | -$912,846 | -$800,173 | -$845,671 | -$772,180 |
| Interest expense | -$1 | $272,245 | $267,008 | $124,985 | $29,547 | $935 | $740 |
| Net income | -$1.38M | -$1.51M | -$2.17M | -$1.31M | -$825,539 | -$840,933 | -$764,577 |
| EBITDA | -$1.38M | -$1.23M | -$1.43M | -$898,332 | -$785,550 | -$831,009 | -$754,355 |
| EPS (basic) | -0.12 | -0.26 | -0.28 | — | -0.17 | -0.17 | -0.16 |
| EPS (diluted) | -0.12 | -0.26 | -0.28 | — | -0.17 | -0.17 | -0.16 |
| Weighted avg. shares (diluted) | 12.96M | 10.79M | 7.66M | — | 4.85M | 4.82M | 4.82M |
| Balance sheet | |||||||
| Cash & equivalents | $3.63M | $4.55M | $4.22M | $1.03M | $1.14M | $1.02M | $1.56M |
| Receivables | $173,985 | $291,486 | $201,481 | $199,954 | — | — | — |
| Inventory | $102,568 | $111,036 | $104,523 | $116,217 | — | — | — |
| Current assets | $4.03M | $5.08M | $4.70M | $1.47M | — | — | — |
| PP&E, net | $24,525 | $33,700 | $45,187 | $56,677 | — | — | — |
| Intangibles | $205,168 | $205,985 | $206,801 | $202,264 | — | — | — |
| Total assets | $5.02M | $6.12M | $5.80M | $4.14M | — | — | — |
| Current liabilities | $2.49M | $2.55M | $2.58M | $2.46M | — | — | — |
| Total liabilities | $2.85M | $2.96M | $3.05M | $4.16M | — | — | — |
| Shareholders' equity | $611,196 | $1.62M | $2.55M | -$19,225 | $108,457 | $351,610 | $1.06M |
| Shares outstanding | 13.37M | 12.25M | 10.44M | 5.44M | — | — | — |
| Cash flow statement | |||||||
| Operating cash flow | -$912,429 | -$605,460 | -$1.29M | -$511,667 | -$385,655 | -$534,105 | -$488,293 |
| Investing cash flow | $0 | -$7,500 | -$5,354 | — | — | — | — |
| Financing cash flow | $0 | $940,001 | $4.49M | $392,799 | $506,561 | $0 | $262,338 |
| Depreciation & amortization | $9,175 | $11,487 | $12,306 | $14,514 | $14,623 | $14,662 | $17,825 |
| Stock-based compensation | $210,397 | $371,300 | $128,440 | $127,230 | $129,650 | $129,650 | $259,300 |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.